Charles River Laboratories (CRL) Tops Q2 EPS by 32c, Lifts Guidance
Get Alerts CRL Hot Sheet
Price: $352.52 +4.13%
EPS Growth %: +22.2%
Financial Fact:
Selling, general and administrative: 85.65M
Today's EPS Names:
INM, TRI, CRVL, More
EPS Growth %: +22.2%
Financial Fact:
Selling, general and administrative: 85.65M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $1.58, $0.32 better than the analyst estimate of $1.26. Revenue for the quarter came in at $682.6 million versus the consensus estimate of $641.63 million.
GUIDANCE:
Charles River Laboratories sees FY2020 EPS of $7.05-$7.35, versus the consensus of $6.91.
- Revenue growth, reported 7.5% – 9.0%
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c
- Core Molding Technologies, Inc. (CMT) Misses Q3 EPS by 3c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share